600594.SS · 益佰制药
China A-shares · RS rating 55 · As of 2026-10-14
| Price | 3.52 CNY |
|---|---|
| 1-day change | -1.7% |
| RS rating (overall / 1M / 3M / 12M) | 55 / 51 / 78 / 49 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 12 / 26 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | -7.9% |
| Distance from 52-week high | +30.4% |
| Market cap (USD) | $425.2M |